Status:
TERMINATED
Hyperoxia and Microvascular Dysfunction
Lead Sponsor:
Université Libre de Bruxelles
Conditions:
Coronary Microvascular Disease
Microvascular Disease
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Coronary artery disease (CAD) pathophysiology involves endothelium-dependent (e.g. nitric oxide, acetylcholine) and -independent (e.g. adenosine) vascular dilation impairment, which have been demonstr...
Eligibility Criteria
Inclusion
- Coronary angiography done in the context of suspicion of coronary artery disease (CAD)
Exclusion
- Respiratory failure requiring intubation or supplementary oxygen
- Severe chronic obstructive pulmonary disease
- Significant arrhythmia precluding waveform analysis (e.g., excessive premature ventricular contractions or atrial fibrillation)
- Severe valvular heart disease,
- Suspected elevated central venous pressure (CVP)
- Heart failure as defined by New York Heart Association class III or IV
- Previous coronary revascularization or heart transplantation
- Severe hypertension (systolic pressure \>200 mmHg and diastolic pressure \>120 mmHg at rest)
- Contraindications to adenosine infusion
- Contraindication to acetylcholine (Ach) infusion
- Severe bronchial asthma.
Key Trial Info
Start Date :
December 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2018
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04321434
Start Date
December 1 2016
End Date
October 1 2018
Last Update
March 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasme Hospital
Brussels, Brabant, Belgium, 1070